Analysts await Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.01 EPS, up 300% or $0.03 from last year’s $-0.04 per share.

At the moment 5 analysts are watching Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), 3 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 5 analysts have a mean sales target of 63.08 million. For the quarter ending Sep-16, 5 analysts have a mean sales target of 66.74 million whilst for the year ending Dec-16, 5 analysts have a mean target of 264.50 million.

In terms of earnings per share, 4 analysts have a -0.02 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 4 analysts have a 0.01 EPS mean target and for the quarter ending Sep-16 there are 4 estimates of -0.01 EPS.

The biggest institutional shareholders in Amphastar Pharmaceuticals, Inc. include Federated Global Inv Mgmt Corp which owns 1 million shares in the company valued at $21.13 million. BlackRock Fund Advisors is the second biggest holder with 1 million shares currently valued at 19.52 million whilst Vanguard Group Inc has 1 million shares valued at 17.97 million.

Total shares held by institutions as of the most recent company filings are 14,354,240 with a reported 1,575,372 bought and 1,143,603 sold. These holdings make up 32.11% of the company’s outstanding shares.

Currently insiders hold 582,619 shares in the business which makes up 1.30% of shares. The biggest holder currently is Dr. Jack Yongfeng Zhang who owns 1,088,335 shares (2.42% of those outstanding), whilst Mr. Jason B. Shandell holds 227,588 (0.51% of shares outstanding) and Mr. Richard Koo, C.P.A. holds 223,408 (0.50% of shares outstanding).

The stock decreased 0.85% or $0.1 during the last trading session, hitting $12.17. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has fallen 4.11% over the past 6 months and is downtrending.